DexCom, Inc. (DXCM) SEC Filings & Earnings Calls
EquiReason read 17 DexCom, Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-09-14 — DexCom promoted CFO Jereme Sylvain to also serve as COO, expanding his role to oversee global operations and quality teams, effective September 14, 2026..
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 29.4B
- P/E TTM
- 30.9
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Feb, in 109 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
30 Jul 20268-K · 2.02DexCom reported Q2 2026 revenue of $1.308B (up 13% YoY), GAAP operating income $318.3M (24.3% margin, +590bps YoY), non-GAAP EPS $0.70 (up 45.8% YoY). Raised FY2026 revenue midpoint and margin guidance. Positive CONNECT trial results.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $1.31B | +13% y/y |
| Organic revenue growth · Q2-2026 | 12.0% | |
| U.S. revenue growth · U.S. · Q2-2026 | 11.0% | |
| International revenue growth · International · Q2-2026 | 19.0% | |
| GAAP gross profit · Q2-2026 | $830M | +21% y/y |
| GAAP gross margin · Q2-2026 | 63.4% | |
| Non-GAAP gross profit · Q2-2026 | $839M | |
| Non-GAAP gross margin · Q2-2026 | 64.1% | |
| GAAP operating income · Q2-2026 | $318M | +50% y/y |
| GAAP operating margin · Q2-2026 | 24.3% |
Guidance
FY2026 revenue raised to $5.18-5.25B (approx 11-13% growth); Non-GAAP gross profit margin ~64%; Non-GAAP operating margin ~23.5-24%; Adjusted EBITDA margin ~31.5-32%.
Raised FY2026 revenue midpoint and increased margin guidance across all metrics, reflecting strong operational performance and confidence in growth trajectory
Risks flagged
No significant risk signals identified; strong financial performance and guidance raise
“Revenue growth, margin expansion, and positive clinical trial results”
30 Jul 202610-QDexCom reported Q2 2026 revenue up 13% YoY, operating income up 50%, and net income up 39%, with strong cash flow and active buybacks.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $1.31B | +13% y/y |
| Gross profit · Q2-2026 | $830M | +21% y/y |
| Operating income · Q2-2026 | $318M | +50% y/y |
| Net income · Q2-2026 | $249M | +39% y/y |
| Diluted net income per share · Q2-2026 | $0.64 | +42% y/y |
| Operating cash flow · H1-2026 | $795M | +63% y/y |
| Share repurchases · H1-2026 | $604M |
Risks flagged
Inventory obsolescence from product transition
“We recorded inventory reserve charges of $45.6 million and $8.8 million, during the three months ended June 30, 2026 and 2025, respectively.”
Litigation exposure
“Due to uncertainty surrounding the securities class action litigation, the derivative actions, and the G6 and G7 Class Action Litigation, we are unable to reasonably estimate the ultimate outcome.” · word for word
15 May 20268-K · 7.01, 8.01Issued a Regulation FD disclosure (forward guidance or material update); disclosed a material event under other events (litigation, recall, contract loss, or major announcement)open
Guidance
Long-range targets indicate strong revenue growth and margin expansion; positive outlook.
30 Apr 202610-QRevenue $1.19B (+15% y/y); Net income $200M (+89% y/y); Operating cash flow $526M (+186% y/y)open
Figures in the filing · each found in the filing text
| Revenue · Q1-2026 | $1.19B | +15% y/y |
| Net income · Q1-2026 | $200M | +89% y/y |
| Operating cash flow · Q1-2026 | $526M | +186% y/y |
| Free cash flow · Q1-2026 | $449M | +364% y/y |
| Gross margin · Q1-2026 | 62.9% | |
| Operating margin · Q1-2026 | 21.4% | |
| Revenue growth · Q1-2026 | 15.0% | |
| Buyback authorization · 2025-04 | $750M |
Risks flagged
Inventory obsolescence risk
“We recorded excess and obsolete inventory charges of $38.6 million and $28.2 million, during the three months ended March 31, 2026 and 2025, respectively.” · word for word
Litigation risk
“We are subject to various claims, complaints and legal actions... including securities class action litigation, derivative actions, and G6 and G7 Class Action Litigation.” · word for word
30 Apr 20268-K · 2.02Revenue $1.19B (+15% y/y); GAAP operating income $255M (+91% y/y); GAAP net income $200M (+89% y/y); Guidance: Non-GAAP Operating Margin raised to ~23-23.5% (from prior ~22-23%); Adjusted EBITDA Margin raised to ~31-31.5% (from prior ~30-31earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q1-2026 | $1.19B | +15% y/y |
| GAAP operating income · Q1-2026 | $255M | +91% y/y |
| GAAP net income · Q1-2026 | $200M | +89% y/y |
| Non-GAAP operating margin · Q1-2026 | 22.2% | |
| Cash and marketable securities · Q1-2026 | $2.42B |
Guidance
Non-GAAP Operating Margin raised to ~23-23.5% (from prior ~22-23%); Adjusted EBITDA Margin raised to ~31-31.5% (from prior ~30-31%). Revenue guidance reiterated at $5.16-$5.25B.
DexCom raised FY2026 margin guidance on strong Q1 beat, with revenue growth accelerating and significant operating leverage.
Risks flagged
No material risk signals; strong cash position and undrawn credit facility mitigate liquidity risk.
“Cash balance $2.42B, revolving credit facility undrawn.”
15 Apr 2026DEF 14ADexCom filed its definitive proxy statement (DEF 14A) for the 2026 annual meeting, disclosing executive compensation, governance practices, and financial highlights.open
Figures in the filing · each found in the filing text
| Revenue · FY2025 | $4.66B | +16% y/y |
| Gross Profit · FY2025 | $2.80B | +15% y/y |
| Operating Income · FY2025 | $912M | +52% y/y |
| Net Income · FY2025 | $836M | +45% y/y |
| Operating Cash Flow · FY2025 | $1.44B | +46% y/y |
| Cash, Cash Equivalents and Short-term Marketable Securities · FY2025 | $2.00B | |
| Active Customer Base · FY2025 | 3,500,000 | +20% y/y |
| Share Repurchase Authorization · FY2025 | $750M | |
| Share Repurchases Executed · FY2025 | $500M |
Risks flagged
CEO Transition Execution Risk
“Kevin Sayer took a medical leave of absence effective from September 14, 2025 to March 2, 2026.”
Competitive Pressure
“Given the focus on reducing healthcare costs, trends in the healthcare industry and changing regulation, the pricing pressure from payors, and increased competition, we anticipated that it would be challenging to maintain a rapid rate of growth during fiscal 2025.” · word for word
12 Feb 20268-K · 2.02Revenue $1.26B (+13% y/y); GAAP operating income $323M; Non-GAAP operating margin 26.3; Guidance: FY2026 revenue $5.16-$5.25B, 11-13% growth; operating margin 22-23%; EBITDA margin 30-31%.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q4-2025 | $1.26B | +13% y/y |
| GAAP operating income · Q4-2025 | $323M | |
| Non-GAAP operating margin · Q4-2025 | 26.3% |
Guidance
FY2026 revenue $5.16-$5.25B, 11-13% growth; operating margin 22-23%; EBITDA margin 30-31%.
Strong guidance with revenue growth, margin expansion, and new product momentum.
Risks flagged
Foreign exchange impact on international revenue; competitive pressure in CGM market.
“Organic revenue excludes $9.4M FX impact in Q4 2025.”
12 Jan 20268-K · 2.02Annual revenue $4.60B; Guidance: Initial FY2026 guidance providedearningsopen
Figures in the filing · each found in the filing text
| Annual revenue · FY2025 | $4.60B |
Guidance
Initial FY2026 guidance provided
DexCom provided initial FY2026 guidance with positive outlook, supported by product innovations and expanded coverage.
Risks flagged
Preliminary results subject to finalization; guidance may change.
“preliminary, unaudited financial results for the fourth quarter of 2025 and fiscal year 2025, initial financial outlook for fiscal year 2026.” · word for word
22 Dec 20258-K · 5.02CEO base salary $1M; CEO target bonus percentage 150; RSU grant value $8Mopen
Figures in the filing · each found in the filing text
| CEO base salary · FY2026 | $1M | |
| CEO target bonus percentage · FY2026 | 150.0% | |
| RSU grant value · Q4-2025 | $8M | |
| PSU target value · Q4-2025 | $8M |
Risks flagged
CEO transition during prior CEO's medical leave creates leadership uncertainty; return timeline uncertain.
“Mr. Sayer’s medical leave of absence ... Board currently expects Mr. Sayer to return on or about March 2026” · word for word
30 Oct 202510-QDexCom reported strong Q3 2025 results with revenue up 21.6% YoY, net income more than doubling, and significant operating cash flow improvement.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q3-2025 | $1.21B | +22% y/y |
| Net income · Q3-2025 | $284M | +111% y/y |
| Operating cash flow · 9M-2025 | $1.15B | +67% y/y |
| Free cash flow · 9M-2025 | $885M | +95% y/y |
| Gross margin · Q3-2025 | 60.5% |
Risks flagged
Customer concentration / rebate exposure
“Accrued rebates $1,373.3 million as of September 30, 2025, up from $1,135.9 million at December 31, 2024.”
Inventory obsolescence
“Excess and obsolete inventory charges of $53.0 million during the nine months ended September 30, 2025, up from $32.7 million in the prior year period.”
30 Oct 20258-K · 2.02Revenue $1.21B (+22% y/y); GAAP operating income $242M (+60% y/y); Non-GAAP operating income $273M (+29% y/y); Guidance: FY2025 revenue $4.630-$4.650 billion (~15% growth)earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q3-2025 | $1.21B | +22% y/y |
| GAAP operating income · Q3-2025 | $243M | +60% y/y |
| Non-GAAP operating income · Q3-2025 | $273M | +29% y/y |
| GAAP net income · Q3-2025 | $284M | +111% y/y |
| Non-GAAP diluted EPS · Q3-2025 | $0.61 | +36% y/y |
| U.S. revenue growth · U.S. · Q3-2025 | 21.0% | |
| International revenue growth · International · Q3-2025 | 22.0% | |
| Cash and marketable securities · Q3-2025 | $3.32B |
Guidance
FY2025 revenue $4.630-$4.650 billion (~15% growth)
Raising FY2025 revenue guidance to $4.63-$4.65B, with Non-GAAP gross margin ~61%, operating margin 20-21%, EBITDA margin 29-30%.
Risks flagged
Competition in CGM market could pressure growth and margins.
“Not explicitly mentioned but inherent in the market.”
DexCom, Inc. — questions
- What did DexCom, Inc. file recently?
- 17 SEC filings in the last 12 months. Latest: 8-K on 2026-09-14 — DexCom promoted CFO Jereme Sylvain to also serve as COO, expanding his role to oversee global operations and quality teams, effective September 14, 2026.
Every figure on this page comes from DexCom, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.